---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-23-000013"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2023-02-10T23:59:59+00:00"
generated_at: "2026-06-19T18:53:26.173645+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Neurocrine Biosciences adopts proxy access bylaw and updates stockholder nomination procedures

## Summary
- Proxy access: stockholder(s) holding 3%+ for 3+ years can nominate up to 2 or 20% of directors.
- Updated procedural requirements for nominations and proposals, including Rule 14a-19 compliance.
- Nominees must provide updated disclosures as of the record date and 5 business days before the meeting.
- Nominations disregarded if stockholder fails to comply with Rule 14a-19 or provide timely evidence.
- Consent actions require notice to fix record date and use of independent inspectors to validate consents.

## SEC filing metadata
- accession: 0000914475-23-000013
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2023-02-10T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447523000013/0000914475-23-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447523000013/nbix-20230210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-23-000013
- JSON: https://secwatch.observer/filing/0000914475-23-000013.json
- Plain text: https://secwatch.observer/filing/0000914475-23-000013.txt

## Key facts
- Governance Changes
  NEUROCRINE BIOSCIENCES INC: Amended and restated Bylaws to implement a proxy access provision and update procedural requirements for stockholder nominations and proposals (effective 2023-02-09).
  - Change: bylaw amendment
  - Effective: 2023-02-09
  source text: On February 9, 2023, the board of directors (the “Board”) of Neurocrine Biosciences, Inc. (the “Company”) amended and restated the Company’s Bylaws (the “Restated Bylaws”) which became effective immediately upon adoption by the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/914475/000091447523000013/0000914475-23-000013-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.